Jorgesotor

@uc.cl

Department of Molecular Genetics and Microbiology, Faculty of Biological Sciences.
Pontifical Catholic University of Chile, Santiago, Chile.

My name is Jorge Soto Ramírez, I am a Biotechnologist graduated in 2012 from the Santo Tomás University, where my interest in immunology began. During my undergraduate studies, I began my thesis at the Public Health Institute of Chile, in the Biotechnology Section under the tuition of Dr. Abel Vásquez, with whom I worked on the development of a prototype vaccine against Streptococcus agalactiae (GBS) and the development of a detection kit against this same pathogen under the FONDEF D10I1202 project.
Later, in 2014 I entered the doctoral program in Biological Sciences. Molecular Genetic Mention and Microbiology of the Pontifical Catholic University of Chile. Here I started working with Dr. Alexis Kalergis on different projects within which, I ended up evaluating the humoral immune response induced by two recombinant vaccines against the human respiratory syncytial virus (RSV) and human metapneumovirus (MPV). This work allowed me to be awarded at the International Congress of Immunology ALAI 2018 and be considered with the distinction of “Merito” in the congress organized by the Federation of Clinical Immunology Societies (FOCIS) 2019. In addition, during this process, I was able to participate in the development of the first clinical study conducted in Chile to evaluate a vaccine against RSV.
In October 2018, I obtained my Ph.D. degree in Biological Sciences and in January 2019 I awarded my Postdoctoral FONDECYT with the first place on the table, under the direction of Dr. Susan Bueno. My current interests are focused on immunology, more specifically on understanding how respiratory pathogens can modulate an inefficient immune response in the host, suppressing the adaptive immune response (current postdoctoral project)

EDUCATION

1. Postdoctoral Researcher in Pontifical Catholic University of Chile. 2019 to date.
2. PhD in Biological Science. Mention in Molecular Genetic and Microbiology. Pontifical Catholic University of to 2018.
3. Master’s degree in Biological Science. Pontifical Catholic University of Chile. 2014 to 2015.
4. Biotechnology degree. Santo Tomás University. 2007 to 2012.

RESEARCH INTERESTS

My interests are focused on the study of immunology and the development of vaccines and therapies. However, thanks to this, the study of B cells and how they can be stimulated for maturation and differentiation to plasma or memory cells has become one of my main interests today.

1057

Scholar Citations

20

Scholar h-index

29

Scholar i10-index

RECENT SCHOLAR PUBLICATIONS

  • IMMUNOGENIC FORMULATION CONTAINING ONE OR MORE MODIFIED BCG STRAINS EXPRESSING A SARS-CoV-2 PROTEIN, USEFUL FOR PREVENTING, TREATING, OR ATTENUATING THE DEVELOPMENT OF COVID-19
    AK PARRA, SB RAMREZ, PG MUOZ, AR DIAZ, JS RAMIREZ
    US Patent App. 18/258,943 2024

  • Human metapneumovirus respiratory infection affects both innate and adaptive intestinal immunity
    J Seplveda-Alfaro, EA Cataln, OP Vallejos, I Ramos-Tapia, ...
    Frontiers in Immunology 15, 1330209 2024

  • Understanding the neurotrophic virus mechanisms and their potential effect on systemic lupus erythematosus development
    FR Uribe, VPI Gonzlez, AM Kalergis, JA Soto, K Bohmwald
    Brain Sciences 14 (1), 59 2024

  • Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents
    D Rivera, C Mndez, B Diethelm-Varela, F Melo-Gonzalez, Y Vazquez, ...
    Frontiers in Immunology 15, 1372193 2024

  • New developments and challenges in antibody-based therapies for the respiratory syncytial virus
    B Diethelm-Varela, JA Soto, CA Riedel, SM Bueno, AM Kalergis
    Infection and Drug Resistance, 2061-2074 2023

  • A molecular perspective for the development of antibodies against the human respiratory syncytial virus
    RA Loaiza, RA Ramrez, J Seplveda-Alfaro, MA Ramrez, CA Andrade, ...
    Antiviral Research, 105783 2023

  • Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open
    N Le Corre, K Abarca, P Astudillo, M Potin, S Lpez, M Goldsack, ...
    Vaccines 11 (10), 1526 2023

  • Current and emerging pharmacological treatments for respiratory syncytial virus infection in high-risk infants
    JA Soto, RA Loaiza, S Echeverra, RA Ramrez, AM Kalergis
    Expert Opinion on Pharmacotherapy 24 (10), 1143-1158 2023

  • Compositional Changes in Sediment Microbiota Are Associated with Seasonal Variation of the Water Column in High-Altitude Hyperarid Andean Lake Systems
    I Ramos-Tapia, P Salinas, R Nez, D Cortez, J Soto, M Paneque
    Microbiology Spectrum 11 (3), e05200-22 2023

  • Cholic and deoxycholic acids induce mitochondrial dysfunction, impaired biogenesis and autophagic flux in skeletal muscle cells
    J Abrigo, H Olgun, F Tacchi, J Orozco-Aguilar, M Valero-Breton, J Soto, ...
    Biological Research 56 (1), 30 2023

  • Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
    C Mndez, HF Pealoza, BM Schultz, A Pia-Iturbe, M Ros, ...
    EBioMedicine 91 2023

  • Involvement of trained immunity during autoimmune responses
    VP Mora, RA Loaiza, JA Soto, K Bohmwald, AM Kalergis
    Journal of Autoimmunity 137, 102956 2023

  • Immune responses at host barriers and their importance in systemic autoimmune diseases
    K Schinnerling, HA Penny, JA Soto, F Melo-Gonzalez
    Advances in Molecular Pathology, 3-24 2023

  • Ex Situ Conservation of Atriplex taltalensis I.M. Johnst. via In Vitro Culturing of Its Axillary Shoots
    C Muoz-Alcayaga, J Soto, C Romn-Figueroa, M Paneque
    Diversity 15 (1), 13 2022

  • Inactivated vaccine-induced SARS-CoV-2 variant-specific immunity in children
    JA Soto, F Melo-Gonzlez, C Gutierrez-Vera, BM Schultz, ...
    Mbio 13 (6), e01311-22 2022

  • SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study
    M Dib, N Le Corre, C Ortiz, D Garca, M Ferrs, C Martinez-Valdebenito, ...
    The Lancet Regional Health–Americas 16 2022

  • From animal studies into clinical trials: the relevance of animal models to develop vaccines and therapies to reduce disease severity and prevent hRSV infection
    JA Soto, NMS Galvez, DB Rivera, FE Daz, CA Riedel, SM Bueno, ...
    Expert Opinion on Drug Discovery 17 (11), 1237-1259 2022

  • Study of wetland soils of the Salar de Atacama with different azonal vegetative formations reveals changes in the microbiota associated with hygrophile plant type on the soil
    I Ramos-Tapia, R Nuez, C Salinas, P Salinas, J Soto, M Paneque
    Microbiology Spectrum 10 (5), e00533-22 2022

  • Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
    NMS Glvez, GA Pacheco, BM Schultz, F Melo-Gonzlez, JA Soto, ...
    Elife 11, e81477 2022

  • Modulation of immune cells as a therapy for cutaneous lupus erythematosus
    JA Soto, F Melo-Gonzlez, CA Riedel, SM Bueno, AM Kalergis
    International Journal of Molecular Sciences 23 (18), 10706 2022

MOST CITED SCHOLAR PUBLICATIONS

  • Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile
    SM Bueno, K Abarca, PA Gonzlez, NMS Glvez, JA Soto, LF Duarte, ...
    Clinical Infectious Diseases 75 (1), e792-e804 2022
    Citations: 102

  • Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
    F Melo-Gonzlez, JA Soto, LA Gonzlez, J Fernndez, LF Duarte, ...
    Frontiers in immunology 12, 747830 2021
    Citations: 75

  • Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
    SM Bueno, K Abarca, PA Gonzlez, NMS Glvez, JA Soto, LF Duarte, ...
    MedRxiv 2021
    Citations: 71

  • Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine
    LF Duarte, NMS Glvez, C Iturriaga, F Melo-Gonzlez, JA Soto, ...
    Frontiers in immunology 12, 742914 2021
    Citations: 66

  • The role of dendritic cells during infections caused by highly prevalent viruses
    JA Soto, NMS Glvez, CA Andrade, GA Pacheco, K Bohmwald, ...
    Frontiers in Immunology 11, 1513 2020
    Citations: 60

  • Human metapneumovirus: mechanisms and molecular targets used by the virus to avoid the immune system
    JA Soto, NMS Glvez, FM Benavente, MS Pizarro-Ortega, MK Lay, ...
    Frontiers in immunology 9, 2466 2018
    Citations: 47

  • Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity
    JA Soto, NMS Glvez, CA Rivera, CE Palavecino, PF Cspedes, ...
    Frontiers in immunology 9, 2875 2018
    Citations: 46

  • Antibody development for preventing the human respiratory syncytial virus pathology
    JA Soto, NMS Glvez, GA Pacheco, SM Bueno, AM Kalergis
    Molecular Medicine 26, 1-10 2020
    Citations: 38

  • Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial
    K Abarca, E Rey-Jurado, N Muoz-Durango, Y Vzquez, JA Soto, ...
    EClinicalMedicine 27 2020
    Citations: 35

  • A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus
    E Rey-Jurado, J Soto, N Glvez, AM Kalergis
    Human vaccines & immunotherapeutics 13 (9), 2092-2097 2017
    Citations: 33

  • Current insights in the development of efficacious vaccines against RSV
    JA Soto, LM Stephens, KA Waldstein, G Canedo-Marroqun, SM Varga, ...
    Frontiers in immunology 11, 547662 2020
    Citations: 31

  • Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients
    L Muoz-Espinosa, G Alarcon, A Mercado-Moreira, P Cordero, ...
    Autoimmunity 44 (7), 543-548 2011
    Citations: 29

  • Characterization of the anti-inflammatory capacity of IL-10-producing neutrophils in response to Streptococcus pneumoniae infection
    LA Gonzlez, F Melo-Gonzlez, VP Sebastin, OP Vallejos, LP Noguera, ...
    Frontiers in immunology 12, 638917 2021
    Citations: 27

  • A booster dose of CoronaVac increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern
    BM Schultz, F Melo-Gonzlez, LF Duarte, NMS Glvez, GA Pacheco, ...
    MBio 13 (4), e01423-22 2022
    Citations: 26

  • Bacterial and viral coinfections with the human respiratory syncytial virus
    GA Pacheco, NMS Glvez, JA Soto, CA Andrade, AM Kalergis
    Microorganisms 9 (6), 1293 2021
    Citations: 23

  • Peripheral blood classical monocytes and plasma interleukin 10 are associated to neoadjuvant chemotherapy response in breast cancer patients
    J Valds-Ferrada, N Muoz-Durango, A Prez-Sepulveda, S Muiz, ...
    Frontiers in immunology 11, 1413 2020
    Citations: 23

  • Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection
    AE Gonzlez, MK Lay, EL Jara, JA Espinoza, RS Gmez, J Soto, ...
    Virulence 8 (6), 685-704 2017
    Citations: 23

  • BCG vaccination induces cross-protective immunity against pathogenic microorganisms
    JA Soto, NMS Glvez, CA Andrade, MA Ramrez, CA Riedel, AM Kalergis, ...
    Trends in Immunology 43 (4), 322-335 2022
    Citations: 22

  • Lung pathology due to hRSV infection impairs blood–brain barrier permeability enabling astrocyte infection and a long-lasting inflammation in the CNS
    K Bohmwald, JA Soto, C Andrade-Parra, A Fernndez-Fierro, ...
    Brain, Behavior, and Immunity 91, 159-171 2021
    Citations: 22

  • The Optimisation of the Expression of Recombinant Surface Immunogenic Protein of Group B Streptococcus in Escherichia coli by Response Surface Methodology
    DA Diaz-Dinamarca, JI Jerias, DA Soto, JA Soto, NV Diaz, YY Leyton, ...
    Molecular biotechnology 60, 215-225 2018
    Citations: 20

Publications

1. Jorge A. Soto, Diego A. Diaz-Dinamarca, Daniel A. Soto, Magaly J. Barrientos, Flavio Carrion, Alexis Kalergis, Abel Vasquez. Cellular immune response induced by Surface Immunogenic Protein with AbISCO-100 adjuvant vaccination decreases Group B Streptococcus vaginal colonization. Mol Immunol. 2019 Jul;111:198-204. doi: 10.1016/j..
2. Benavente FM, Soto JA, Pizarro-Ortega MS, Bohmwald K, González PA, Bueno SM, Kalergis AM. Contribution of IDO to human respiratory syncytial virus infection. J Leukoc Biol. 2019 May 15. doi: 10.1002/.
3. Acevedo OA, Díaz FE, Beals TE, Benavente FM, Soto JA, Escobar-Vera J, González PA, Kalergis AM. Contribution of Fcγ Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus. Front Cell Infect Microbiol. 2019 Mar 29;9:75. doi: 10.3389/.
4. Jorge A. Soto1, Nicolás M. S. Galvez1, Claudia A. Rivera1, Christian E. Palavecino1, Pablo F. Céspedes1, Emma Rey-Jurado1, Susan M. Bueno1, Alexis M. Kalergis*1,2. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective cellular and humoral immunity. Front Immunol. 2018 Dec 6;9:2875. doi: 10.3389/.
5. Jorge A Soto, Nicolas M Galvez, Felipe M Benavente, Magdalena S Pizarro-Ortega,Margarita Kam-Lem Lay, Claudia Riedel, Susan M Bueno, Pablo Alberto Gonzalez, Alexis M Kalergis*. Human Metapneumovirus: mechanisms and molecular targets used by the virus to avoid the immune system. Front Immunol. 2018 Oct 24;9:2466. doi: 10.3389/
6. Diaz-Dinamarca DA, Ibañez FJ, Soto DA, Soto JA, Cespedes PF, Muena NA, Garate DS, Kalergis AM, Vasquez AE. Immunization with a Mixture of Nucleoprotein from Human Metapneumovirus and AbISCO-100 Adjuvant Reduces Viral Infection in Mice Model. Viral Immunol. 2018 May;31(4):306-314. doi: 10.1089/. Epub 2018 Jan 26.
7. Díaz-Dinamarca DA1,2, Jerias JI1, Soto DA1, Soto JA1,2, Díaz NV1, Leyton YY1, Villegas RA3, Kalergis AM2,4, Vásquez AE5,6. The Optimisation of the Expression of Recombinant Surface Immunogenic Protein of Group B Streptococcus in Escherichia coli by Response Surface Methodology Improves Humoral Immunity. Mol Biotechnol. 2018 Mar;60(3):215-225. doi: 10.1007/s12033-018-0065-8.
8. Magdalena S. Pizarro-Ortega1 , Angelo T. Castiglione1 , Nicolás MS. Gálvez1, Jorge A. Soto1 , Natalia Muñoz-Durango1 y Alexis M. Kalergis1,2.Current context of the disease caused for VRSh and development of new treatments. Revista del Instituto de Salud Pública de Chile. RISPCH, Volumen N°1, Número N°1, Año 2017.
9. Gálvez NMS1, Soto JA1, Kalergis AM3,4. New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV. Int J Mol Sci. 2017.
10. Rey-jurado E, Soto J, Gálvez N, Kalergis AM. A safe and efficient BCG vectored vaccine to prevent the disease caused by the humanRespiratory Syncytial Virus. Hum Vaccin Immunother. 2017.
11. Andrea E. González, Margarita K. Lay, Evelyn L. Jara, Janyra A. Espinoza, Roberto S. Gómez, Jorge Soto, Claudia A. Rivera, Katia Abarca, Susan M. Bueno, Claudia A. Riedel, Alexis M. Kalergis. Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection. Virulence. 2017.
12. Rubio DP1, Roa LG2, Soto DA1, Velasquez FJ1, Gregorcic NA1, Soto JA3, Martinez MC4, Kalergis AM5, Vasquez AE6. Purification and characterization of saxitoxin from Mytilus chilensis of southern Chile. Toxicon. 2015

GRANT DETAILS

Funding Agency: FONDECYT
Date: March 2019- March 2022
Role: Postdoctoral Research
Title: Contribution of Myeloid Derived Suppressor Cells (MDSC) in the lung pathology induced by the human metapneumovirus (hMPV) infection

INDUSTRY EXPERIENCE

1. Assistant Research in the project “FONDEF D10I1202”. Biotechnology Section. Department of Environmental Health. Institute of Public Health of Chile. 2012 al 2014.
2.. Assistant Research in the project “CORFO 11IEI-12861”. Virbac-Centrovet Ltda. 2012 al 2014.